Sangamo Therapeutics (SGMO)
(Delayed Data from NSDQ)
$0.96 USD
+0.06 (6.69%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.94 -0.02 (-2.10%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Balance Sheet
Fiscal Year End for Sangamo Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 81 | 278 | 377 | 641 | 362 |
Receivables | 1 | 4 | 6 | 6 | 38 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 12 | 18 | 16 | 12 | 5 |
Total Current Assets | 94 | 300 | 399 | 660 | 405 |
Net Property & Equipment | 27 | 64 | 52 | 41 | 30 |
Investments & Advances | 0 | 30 | 88 | 51 | 22 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 88 | 93 | 101 | 92 |
Deposits & Other Assets | 18 | 19 | 17 | 15 | 11 |
Total Assets | 165 | 563 | 722 | 939 | 638 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 15 | 22 | 10 | 13 | 18 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 32 | 38 | 32 | 39 | 14 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 52 | 86 | 92 | 39 |
Total Current Liabilities | 48 | 112 | 128 | 144 | 70 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 116 | 173 | 252 | 88 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 41 |
Other Non-Current Liabilities | 1 | 1 | 1 | 7 | 6 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 82 | 268 | 347 | 441 | 205 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 2 | 2 | 1 | 1 | 1 |
Capital Surplus | 1,492 | 1,450 | 1,334 | 1,269 | 1,091 |
Retained Earnings | -1,406 | -1,149 | -956 | -778 | -657 |
Other Equity | -5 | -8 | -4 | 5 | -2 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 83 | 295 | 375 | 497 | 433 |
Total Liabilities & Shareholder's Equity | 165 | 563 | 722 | 939 | 638 |
Total Common Equity | 83 | 295 | 375 | 497 | 433 |
Shares Outstanding | 177.30 | 163.80 | 145.60 | 141.40 | 115.90 |
Book Value Per Share | 0.47 | 1.80 | 2.58 | 3.52 | 3.73 |
Fiscal Year End for Sangamo Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 28 | 55 | 81 | 132 | 143 |
Receivables | 1 | 1 | 1 | 2 | 4 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 12 | 13 | 12 | 14 | 13 |
Total Current Assets | 40 | 69 | 94 | 148 | 160 |
Net Property & Equipment | 21 | 22 | 27 | 28 | 61 |
Investments & Advances | 0 | 0 | 0 | 0 | 39 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 14 | 17 | 18 | 16 | 19 |
Total Assets | 93 | 129 | 165 | 220 | 325 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 18 | 15 | 15 | 15 | 15 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 21 | 25 | 32 | 32 | 32 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 1 | 7 |
Total Current Liabilities | 39 | 40 | 48 | 48 | 54 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 1 | 1 | 1 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 69 | 72 | 82 | 85 | 91 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 2 | 2 | 2 | 2 | 2 |
Capital Surplus | 1,519 | 1,516 | 1,492 | 1,486 | 1,480 |
Retained Earnings | -1,492 | -1,455 | -1,406 | -1,346 | -1,242 |
Other Equity | -6 | -6 | -5 | -7 | -6 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 24 | 57 | 83 | 135 | 234 |
Total Liabilities & Shareholder's Equity | 93 | 129 | 165 | 220 | 325 |
Total Common Equity | 24 | 57 | 83 | 135 | 234 |
Shares Outstanding | 207.50 | 207.50 | 177.30 | 177.30 | 171.80 |
Book Value Per Share | 0.11 | 0.27 | 0.47 | 0.76 | 1.36 |